Argenx SE
Forward trial catalysts linked to ARGX
CSA tracks 1 forward catalyst for Argenx SE across 1 asset, spanning Phase 2/3. The nearest is a readout expected Mar 2027 (month precision). Confidence across its tracked catalysts breaks down as 1 medium. Tracked indications include Generalized Myasthenia Gravis, Myasthenia Gravis.
ARGX in the full snapshot
The free sample on this page is a slice. In the current full CSA snapshot, Argenx SE has:
Forward catalysts by year
Every catalyst in the snapshot comes with its date, date confidence and source link.
3 trials behind these assets
| Asset | Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|---|
| efgartigimod | NCT06298552 | Phase 3 | Active, not recruiting | 2025-06-30 | Experimental | argenx | Generalized Myasthenia Gravis; gMG; Myasthenia Gravis, Generalized; Myasthenia Gravis |
| efgartigimod | NCT04833894 catalyst | Phase 2/3 | Recruiting | 2027-03 | Experimental | argenx | Generalized Myasthenia Gravis |
| efgartigimod | NCT07217587 | Phase 3 | Recruiting | 2027-09-28 | Active comparator | Janssen Research & Development, LLC | Myasthenia Gravis |
Every trial the CSA sample links to ARGX's tracked assets, including trials another sponsor runs and trials where the asset is not the experimental arm.
Conditions studied
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This sponsor's catalysts are a slice of the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 →